| Target Price | CN¥360.67 |
| Price | CN¥293.62 |
| Potential |
22.84%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target BeOne Medicines 2026 .
The average BeOne Medicines target price is CN¥360.67.
This is
22.84%
register free of charge
CN¥394.80
34.46%
register free of charge
CN¥278.76
5.06%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend BeOne Medicines to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BeOne Medicines stock has an average upside potential 2026 of
22.84%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion CN¥ | 27.21 | 37.64 |
| 56.19% | 38.32% | |
| EBITDA Margin | -13.43% | 7.70% |
| 72.09% | 157.32% | |
| Net Margin | -18.29% | 3.95% |
| 52.54% | 121.59% |
10 Analysts have issued a sales forecast BeOne Medicines 2025 . The average BeOne Medicines sales estimate is
This results in the following potential growth metrics:
9 BeOne Medicines Analysts have issued a net profit forecast 2025. The average BeOne Medicines net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CN¥ | -3.64 | 1.04 |
| 26.46% | 128.57% | |
| P/E | 267.27 | |
| EV/Sales | 6.77 |
9 Analysts have issued a BeOne Medicines forecast for earnings per share. The average BeOne Medicines EPS is
This results in the following potential growth metrics and future valuations:
BeOne Medicines...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


